![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
In recent years, management of chronic hepatitis C virus (HCV) infection has been revolutionized by the availability of oral direct-acting antivirals (DAAs), which have significantly better efficacy and safety profiles than interferon-containing regimens. Simple, short-duration DAA therapies will facilitate expansion of HCV treatment to nonspecialist providers, which will be vital to achieve the WHO target of eliminating chronic HCV as a major public health threat by 2030. Coformulated glecaprevir/pibrentasvir is the only 8-week, pan-genotypic, 2-DAA regimen recommended by international guidelines as a first-line regimen in treatment-naive, noncirrhotic HCV genotype 1–6 patients. This review provides a comprehensive summary of the pharmacodynamic and pharmacokinetic parameters, efficacy, safety and place in the HCV treatment paradigm for glecaprevir/pibrentasvir.
Author contributions
AbbVie contributed to their design; and participated in the collection, analysis and interpretation of the data and in the writing, reviewing and approval of the publication.
Financial & competing interests disclosure
F Mensa, S Lovell, T Pilot-Matias, W Liu: Employees of AbbVie Inc. and may own AbbVie stock and/or options. AbbVie sponsored the studies (NCT02243280, NCT02243293, NCT02446717, NCT02604017, NCT02640157, NCT02243293, NCT02640482, NCT02636595, NCT02642432, NCT02738138, NCT02651194, NCT02692703). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Medical writing support was provided by Andrew Kerr of Medical Expressions, funded by AbbVie.